血管作動性腸管ペプチド腫瘍の世界市場レポート 2025年

血管作動性腸管ペプチド腫瘍市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.3％で20億5,000万米ドルに成長します。予測期間中の成長は、化学療法に対する需要の高まり、薬剤承認の加速化、経口薬への嗜好の高まり、疾患に対する意識の高まり、腫瘍の有病率の増加などに起因すると考えられます。予測期間における主な動向としては、標的療法の進歩、診断技術の向上、革新的治療法の開発、個別化医療の台頭、新規治療ソリューションの発売などが挙げられます。

標的療法の採用拡大が血管作動性腸管ペプチド（VIP）腫瘍市場の成長を牽引すると予想されます。標的療法は、疾患、特にがんの開発と進行に関与する特定の分子や経路に作用するように設計されており、健康な細胞を温存しながら異常な細胞を選択的に除去することを可能にします。この標的治療の増加は、特定の遺伝子変異を標的とし、副作用を最小限に抑えることで治療効果を向上させる精密医療の進歩によって促進されています。VIP腫瘍の場合、標的療法は腫瘍の増殖とホルモン分泌に関わる重要な経路を阻害することで効果を発揮します。これによりVIPレベルが低下し、激しい下痢などの症状が緩和され、病気の進行が遅くなります。例えば、2024年7月、米国を拠点とする専門組織である米国遺伝子細胞治療学会（ASGCT）は、2024年第2四半期に76件の遺伝子治療試験が開始され、前四半期に比べて25％増加したと報告しました。このように、標的治療の利用拡大がVIP腫瘍市場の拡大に拍車をかけています。

神経内分泌腫瘍の有病率の増加が血管作動性腸管ペプチド腫瘍市場を押し上げると予想されます。神経内分泌腫瘍（NET）は、神経とホルモンを産生する両方の機能を持つ細胞から発生する、まれで遅発性のがんです。罹患率の増加は、診断方法の進歩により、以前は過小診断されていた腫瘍をより早期に、より正確に同定できるようになったことに起因しています。NETのまれなサブセットであるVIP腫瘍は、VIPの過剰分泌が特徴で、重度の水様性下痢や電解質バランスの乱れを引き起こします。例えば、政府機関であるCancer Australiaが2024年9月に発表したところによると、85歳までに神経内分泌腫瘍と診断される生涯リスクは約55人に1人、つまり1.8％です。このリスクは、女性（58人に1人、1.7％）に比べ、男性（52人に1人、1.9％）でわずかに高いです。したがって、神経内分泌腫瘍の発生率の上昇がVIP腫瘍市場の成長に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界血管作動性腸管ペプチド腫瘍PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の血管作動性腸管ペプチド腫瘍市場：成長率分析
• 世界の血管作動性腸管ペプチド腫瘍市場の実績：規模と成長, 2019-2024
• 世界の血管作動性腸管ペプチド腫瘍市場の予測：規模と成長, 2024-2029, 2034F
• 世界血管作動性腸管ペプチド腫瘍総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の血管作動性腸管ペプチド腫瘍市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外科的介入
• 放射線療法
• 化学療法
• 標的療法
• 世界の血管作動性腸管ペプチド腫瘍市場診断別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 画像技術
• 生検
• 超音波内視鏡検査
• 世界の血管作動性腸管ペプチド腫瘍市場治療アプローチ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 緩和ケア
• 治療的治療
• 補助治療
• 世界の血管作動性腸管ペプチド腫瘍市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• がん専門クリニック
• 診断検査室
• 世界の血管作動性腸管ペプチド腫瘍市場、外科的介入の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍切除
• 減量手術
• 低侵襲手術
• 世界の血管作動性腸管ペプチド腫瘍市場放射線治療の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外部放射線治療（EBRT）
• 定位放射線治療（SBRT）
• 陽子線治療
• 世界の血管作動性腸管ペプチド腫瘍市場化学療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 細胞傷害性化学療法
• 併用化学療法
• 術後化学療法と術前化学療法
• 世界の血管作動性腸管ペプチド腫瘍市場標的療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ソマトスタチン類似体療法
• チロシンキナーゼ阻害剤（TKI）
• モノクローナル抗体

第7章 地域別・国別分析

• 世界の血管作動性腸管ペプチド腫瘍市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の血管作動性腸管ペプチド腫瘍市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 血管作動性腸管ペプチド腫瘍市場：競合情勢
• 血管作動性腸管ペプチド腫瘍市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Mayo Clinic Overview, Products and Services, Strategy and Financial Analysis
  • Labcorp Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Mount Sinai Hospital Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Cleveland Clinic Laboratories
• Penn Medicine
• Stanford Health Care
• UCSF Health
• ARUP Laboratories
• Dr. Lal PathLabs
• Cancer Research UK
• Medicover Hospitals
• NuView Life Sciences Inc.
• DNA Labs India
• Inter Science Institute
• Ulta Lab Tests
• True Health Labs
• Ganesh Diagnostic
• Agilus Diagnostics

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 血管作動性腸管ペプチド腫瘍市場2029：新たな機会を提供する国
• 血管作動性腸管ペプチド腫瘍市場2029：新たな機会を提供するセグメント
• 血管作動性腸管ペプチド腫瘍市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

A vasoactive intestinal peptide (VIP) tumor, also known as a VIPoma, is a rare type of neuroendocrine tumor that most commonly originates in the pancreas. It produces excessive amounts of VIP, resulting in symptoms such as profuse watery diarrhea, dehydration, and electrolyte imbalances. Diagnosis is confirmed through elevated VIP levels in the blood, with treatment options including surgery, medications, and targeted therapies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary treatment approaches for vasoactive intestinal peptide tumors include surgical intervention, radiotherapy, chemotherapy, and targeted therapy. Surgical intervention focuses on safely removing localized tumors, alleviating symptoms, and preventing complications, either through complete or minimally invasive resection. Diagnosis is carried out using various methods such as imaging techniques, biopsy, and endoscopic ultrasound. Therapeutic strategies include palliative care, curative treatment, and adjuvant therapy. These treatments are utilized across a range of end-user settings, including hospitals, cancer specialty clinics, and diagnostic laboratories.

The vasoactive intestinal peptide tumor market research report is one of a series of new reports from The Business Research Company that provides vasoactive intestinal peptide tumor market statistics, including the vasoactive intestinal peptide tumor industry global market size, regional shares, competitors with the vasoactive intestinal peptide tumor market share, detailed vasoactive intestinal peptide tumor market segments, market trends, and opportunities, and any further data you may need to thrive in the vasoactive intestinal peptide tumor industry. This vasoactive intestinal peptide tumor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The vasoactive intestinal peptide tumor market size has grown strongly in recent years. It will grow from$1.51 billion in 2024 to $1.61 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth during the historic period can be attributed to the rising prevalence of VIP tumors, increased emphasis on research and development activities, growing healthcare awareness, the expansion of healthcare infrastructure, and enhanced collaborations between biotechnology companies and research institutions.

The vasoactive intestinal peptide tumor market size is expected to see strong growth in the next few years. It will grow to$2.05 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth during the forecast period can be attributed to the rising demand for chemotherapy, accelerated drug approvals, growing preference for oral medications, increased disease awareness, and the increasing prevalence of tumors. Key trends in the forecast period include advancements in targeted therapies, improvements in diagnostic techniques, the development of innovative treatment options, the rise of personalized medicine, and the launch of novel therapeutic solutions.

The increasing adoption of targeted therapy is anticipated to drive the growth of the vasoactive intestinal peptide (VIP) tumor market. Targeted therapies are designed to act on specific molecules or pathways involved in the development and progression of diseases, especially cancer, enabling the selective elimination of abnormal cells while sparing healthy ones. This rise in targeted therapies is fueled by advancements in precision medicine, which improve treatment effectiveness by targeting specific genetic mutations and minimizing adverse effects. In the case of VIP tumors, targeted therapies work by inhibiting critical pathways responsible for tumor growth and hormone secretion. This reduces VIP levels, alleviates symptoms such as intense diarrhea, and slows disease progression. For example, in July 2024, the American Society of Gene and Cell Therapy (ASGCT), a U.S.-based professional organization, reported that 76 gene therapy trials were initiated in the second quarter of 2024, a 25% increase compared to the previous quarter. Thus, the growing use of targeted therapy is fueling the expansion of the VIP tumor market.

The growing prevalence of neuroendocrine tumors is expected to boost the vasoactive intestinal peptide tumor market. Neuroendocrine tumors (NETs) are uncommon, slow-developing cancers originating from cells that have both nerve and hormone-producing functions. Their rising incidence is attributed to advancements in diagnostic methods, which allow for earlier and more precise identification of tumors that were previously underdiagnosed. VIP tumors, a rare subset of NETs, are marked by excessive secretion of VIP, leading to severe watery diarrhea and disturbances in electrolyte balance. For instance, in September 2024 by Cancer Australia, a government agency, the lifetime risk of being diagnosed with neuroendocrine tumors by age 85 is about 1 in 55, or 1.8%. This risk is slightly higher in males (1 in 52 or 1.9%) compared to females (1 in 58 or 1.7%). Therefore, the rising incidence of neuroendocrine tumors is contributing to the growth of the VIP tumor market.

Leading companies in the vasoactive intestinal peptide tumor market are investing in the development of innovative products, including long-acting injectable suspensions, to enhance treatment efficacy, boost patient adherence, and offer prolonged symptom control. These formulations gradually release the active ingredient over time, reducing the frequency of administration. For instance, in October 2024, Teva Pharmaceutical Industries Ltd., a U.S.-based pharmaceutical firm, introduced the first generic version of Sandostatin LAR Depot (octreotide acetate for injectable suspension) in the United States. This drug is used for long-term therapy in acromegaly patients who have not responded adequately to surgery or radiation. It also treats severe diarrhea and flushing associated with metastatic carcinoid tumors and VIP-secreting tumors. The launch highlights Teva's capabilities in developing complex generics and supports its strategy of maintaining a solid foothold in the generic drug market.

Major players in the vasoactive intestinal peptide tumor market are Pfizer Inc., Novartis AG, Mayo Clinic, Labcorp Holdings Inc., Mount Sinai Hospital, Cleveland Clinic Laboratories, Penn Medicine, Stanford Health Care, UCSF Health, ARUP Laboratories, Dr. Lal PathLabs, Cancer Research UK, Medicover Hospitals, NuView Life Sciences Inc., DNA Labs India, Inter Science Institute, Ulta Lab Tests, True Health Labs, Ganesh Diagnostic, and Agilus Diagnostics.

North America was the largest region in the vasoactive intestinal peptide tumor market in 2024. The regions covered in vasoactive intestinal peptide tumor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vasoactive intestinal peptide tumor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vasoactive intestinal peptide tumor market consists of revenues earned by entities by providing services such as genetic testing, immunotherapy, hormone therapy, nuclear medicine, personalized medicine, palliative care, clinical trials, and telemedicine consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The vasoactive intestinal peptide (VIP) Tumor market also includes sales of diagnostic kits, biopsy needles, imaging systems, radiation therapy equipment, chemotherapy drugs, targeted therapy drugs, surgical instruments, and supportive care medications. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vasoactive Intestinal Peptide Tumor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vasoactive intestinal peptide tumor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vasoactive intestinal peptide tumor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vasoactive intestinal peptide tumor market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Surgical Intervention; Radiotherapy; Chemotherapy; Targeted Therapy
• 2) By Diagnosis: Imaging Techniques; Biopsy; Endoscopic Ultrasound
• 3) By Therapeutic Approach: Palliative Care; Curative Treatment; Adjuvant Treatment
• 4) By End-User: Hospitals; Cancer Specialty Clinics; Diagnostic Laboratories
• Subsegments:
• 1) By Surgical Intervention: Tumor Resection; Debulking Surgery; Minimally Invasive Surgery
• 2) By Radiotherapy: External Beam Radiation Therapy (EBRT); Stereotactic Body Radiation Therapy (SBRT); Proton Therapy
• 3) By Chemotherapy: Cytotoxic Chemotherapy; Combination Chemotherapy; Adjuvant And Neoadjuvant Chemotherapy
• 4) By Targeted Therapy: Somatostatin Analog Therapy; Tyrosine Kinase Inhibitors (TKIs); Monoclonal Antibodies
• Companies Mentioned: Pfizer Inc.; Novartis AG; Mayo Clinic; Labcorp Holdings Inc.; Mount Sinai Hospital
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Vasoactive Intestinal Peptide Tumor Market Characteristics

3. Vasoactive Intestinal Peptide Tumor Market Trends And Strategies

4. Vasoactive Intestinal Peptide Tumor Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Vasoactive Intestinal Peptide Tumor Growth Analysis And Strategic Analysis Framework

• 5.1. Global Vasoactive Intestinal Peptide Tumor PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Vasoactive Intestinal Peptide Tumor Market Growth Rate Analysis
• 5.4. Global Vasoactive Intestinal Peptide Tumor Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Vasoactive Intestinal Peptide Tumor Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Vasoactive Intestinal Peptide Tumor Total Addressable Market (TAM)

6. Vasoactive Intestinal Peptide Tumor Market Segmentation

• 6.1. Global Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgical Intervention
• Radiotherapy
• Chemotherapy
• Targeted Therapy
• 6.2. Global Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Imaging Techniques
• Biopsy
• Endoscopic Ultrasound
• 6.3. Global Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Palliative Care
• Curative Treatment
• Adjuvant Treatment
• 6.4. Global Vasoactive Intestinal Peptide Tumor Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Cancer Specialty Clinics
• Diagnostic Laboratories
• 6.5. Global Vasoactive Intestinal Peptide Tumor Market, Sub-Segmentation Of Surgical Intervention, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tumor Resection
• Debulking Surgery
• Minimally Invasive Surgery
• 6.6. Global Vasoactive Intestinal Peptide Tumor Market, Sub-Segmentation Of Radiotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• External Beam Radiation Therapy (EBRT)
• Stereotactic Body Radiation Therapy (SBRT)
• Proton Therapy
• 6.7. Global Vasoactive Intestinal Peptide Tumor Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cytotoxic Chemotherapy
• Combination Chemotherapy
• Adjuvant And Neoadjuvant Chemotherapy
• 6.8. Global Vasoactive Intestinal Peptide Tumor Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Somatostatin Analog Therapy
• Tyrosine Kinase Inhibitors (TKIs)
• Monoclonal Antibodies

7. Vasoactive Intestinal Peptide Tumor Market Regional And Country Analysis

• 7.1. Global Vasoactive Intestinal Peptide Tumor Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Vasoactive Intestinal Peptide Tumor Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Vasoactive Intestinal Peptide Tumor Market

• 8.1. Asia-Pacific Vasoactive Intestinal Peptide Tumor Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Vasoactive Intestinal Peptide Tumor Market

• 9.1. China Vasoactive Intestinal Peptide Tumor Market Overview
• 9.2. China Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Vasoactive Intestinal Peptide Tumor Market

• 10.1. India Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Vasoactive Intestinal Peptide Tumor Market

• 11.1. Japan Vasoactive Intestinal Peptide Tumor Market Overview
• 11.2. Japan Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Vasoactive Intestinal Peptide Tumor Market

• 12.1. Australia Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Vasoactive Intestinal Peptide Tumor Market

• 13.1. Indonesia Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Vasoactive Intestinal Peptide Tumor Market

• 14.1. South Korea Vasoactive Intestinal Peptide Tumor Market Overview
• 14.2. South Korea Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Vasoactive Intestinal Peptide Tumor Market

• 15.1. Western Europe Vasoactive Intestinal Peptide Tumor Market Overview
• 15.2. Western Europe Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Vasoactive Intestinal Peptide Tumor Market

• 16.1. UK Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Vasoactive Intestinal Peptide Tumor Market

• 17.1. Germany Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Vasoactive Intestinal Peptide Tumor Market

• 18.1. France Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Vasoactive Intestinal Peptide Tumor Market

• 19.1. Italy Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Vasoactive Intestinal Peptide Tumor Market

• 20.1. Spain Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Vasoactive Intestinal Peptide Tumor Market

• 21.1. Eastern Europe Vasoactive Intestinal Peptide Tumor Market Overview
• 21.2. Eastern Europe Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Vasoactive Intestinal Peptide Tumor Market

• 22.1. Russia Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Vasoactive Intestinal Peptide Tumor Market

• 23.1. North America Vasoactive Intestinal Peptide Tumor Market Overview
• 23.2. North America Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Vasoactive Intestinal Peptide Tumor Market

• 24.1. USA Vasoactive Intestinal Peptide Tumor Market Overview
• 24.2. USA Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Vasoactive Intestinal Peptide Tumor Market

• 25.1. Canada Vasoactive Intestinal Peptide Tumor Market Overview
• 25.2. Canada Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Vasoactive Intestinal Peptide Tumor Market

• 26.1. South America Vasoactive Intestinal Peptide Tumor Market Overview
• 26.2. South America Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Vasoactive Intestinal Peptide Tumor Market

• 27.1. Brazil Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Vasoactive Intestinal Peptide Tumor Market

• 28.1. Middle East Vasoactive Intestinal Peptide Tumor Market Overview
• 28.2. Middle East Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Vasoactive Intestinal Peptide Tumor Market

• 29.1. Africa Vasoactive Intestinal Peptide Tumor Market Overview
• 29.2. Africa Vasoactive Intestinal Peptide Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Vasoactive Intestinal Peptide Tumor Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Vasoactive Intestinal Peptide Tumor Market, Segmentation By Therapeutic Approach, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Vasoactive Intestinal Peptide Tumor Market Competitive Landscape And Company Profiles

• 30.1. Vasoactive Intestinal Peptide Tumor Market Competitive Landscape
• 30.2. Vasoactive Intestinal Peptide Tumor Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Mayo Clinic Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Labcorp Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Mount Sinai Hospital Overview, Products and Services, Strategy and Financial Analysis

31. Vasoactive Intestinal Peptide Tumor Market Other Major And Innovative Companies

• 31.1. Cleveland Clinic Laboratories
• 31.2. Penn Medicine
• 31.3. Stanford Health Care
• 31.4. UCSF Health
• 31.5. ARUP Laboratories
• 31.6. Dr. Lal PathLabs
• 31.7. Cancer Research UK
• 31.8. Medicover Hospitals
• 31.9. NuView Life Sciences Inc.
• 31.10. DNA Labs India
• 31.11. Inter Science Institute
• 31.12. Ulta Lab Tests
• 31.13. True Health Labs
• 31.14. Ganesh Diagnostic
• 31.15. Agilus Diagnostics

32. Global Vasoactive Intestinal Peptide Tumor Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Vasoactive Intestinal Peptide Tumor Market

34. Recent Developments In The Vasoactive Intestinal Peptide Tumor Market

35. Vasoactive Intestinal Peptide Tumor Market High Potential Countries, Segments and Strategies

• 35.1 Vasoactive Intestinal Peptide Tumor Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Vasoactive Intestinal Peptide Tumor Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Vasoactive Intestinal Peptide Tumor Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r35013_Vasoactive_Intestinal_Peptide_Tumor_GMR_2025